Targeting inflammatory pathways for tumor radiosensitization.
about
DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of RadioresistanceNeem components as potential agents for cancer prevention and treatmentDynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells.Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancerIdentifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Alterations of cell cycle control proteins SHP‑1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cellsCacospongionolide and scalaradial, two marine sesterterpenoids as potent apoptosis-inducing factors in human carcinoma cell linesRadiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound.Involvement of ERK-Nrf-2 signaling in ionizing radiation induced cell death in normal and tumor cells.Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy.WAVE3-NFκB interplay is essential for the survival and invasion of cancer cells.Guggulsterone-mediated enhancement of radiosensitivity in human tumor cell lines.Radiation, inflammation, and immune responses in cancerRegulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentPentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65.Caffeic Acid Phenethyl Ester Increases Radiosensitivity of Estrogen Receptor-Positive and -Negative Breast Cancer Cells by Prolonging Radiation-Induced DNA Damage.Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis.The role of IL-6 in the radiation response of prostate cancerMembrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo.Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-κB axis.Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapyUse of ultrasound in drug delivery systems: emphasis on experimental methodology and mechanisms.Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.The role of inflammatory pathways in cancer-associated cachexia and radiation resistance.Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy.Friend or foe: emerging role of nuclear factor kappa-light-chain-enhancer of activated B cells in cell senescence.Radiobiological modifiers in clinical radiation oncology: current reality and future potential.Portrait of inflammatory response to ionizing radiation treatment.Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18 F-FDG-PET) in the treatment of bone metastases: results from a 3-arm randomized phase II trial.IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma.Role of interleukin-6 in cancer progression and therapeutic resistance.Integrated analysis of differential miRNA and mRNA expression profiles in human radioresistant and radiosensitive nasopharyngeal carcinoma cellsFAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells.Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.Strategies to optimize radiotherapy based on biological responses of tumor and normal tissue.
P2860
Q26738556-D9A75F7A-DE51-4CB7-8A58-1B0FDC7FC560Q26995699-79A1A475-10F1-4B88-95BE-7EF0BE5C7237Q31090728-88466947-01A2-436E-8EF0-2C4D8260F671Q33567034-75E45081-53B9-416D-BF71-A48D55DA3F2DQ33871724-DE4432FF-044B-48C8-948F-B102251F6087Q33874148-E58EA552-ED07-44FC-88D1-DCF3B1BE2011Q34105208-DECA5262-87E3-40C9-8877-F9B5493608C7Q34234982-61C16B40-B4CF-4BD4-9A6F-483D47583497Q34646655-45A7665B-8CE3-45A4-B212-A0786DC6EDB9Q34776063-F008EED0-DC59-455A-8E0F-402165119A41Q34984011-6DD7D2E8-74E6-4E09-8105-FFC9EB881C98Q35347677-590C8E7D-E32E-4695-8B57-7BC53A17EF66Q35971361-C851576D-22B0-4D6A-B2E3-EBAF4153E527Q36005646-4B1B13C6-E250-49A8-95FD-4A3D028F05B3Q36353046-156DBD8D-D012-480B-850D-6CE8554DE5DAQ36483712-9624EA5E-3271-4E07-9F6A-AC591DAEA8F7Q36744894-23A7D404-ADED-4B37-A647-0F48415399A3Q36768974-4F7B11CA-B316-4FB5-8707-96F34B14A55BQ36997722-69A58F7C-99B0-435D-A137-4EC784F99FBEQ37028843-648C4E1D-1221-40A2-A2B4-462D51F0EEC9Q37031569-C05E94B7-C813-49E3-8A94-E504BCD0B942Q37126178-4C1BA1E5-6A28-4AAE-8C45-FF70080032D2Q37384107-CD3AE67A-A501-4936-8F20-30381B609578Q37476413-BD3BDD2A-8C63-43FE-A43B-B80F73A14492Q37702727-113027A2-5471-49C8-B44E-1B3FBD1A0003Q37714373-F4CB62E9-4D75-422E-A1DC-D75B15D72421Q38012534-48403879-3D22-461C-B4AE-330D247EC211Q38052131-2D02B63E-9DC3-475E-A240-FCDD1D0B2C03Q38115997-ACC4A542-C72D-44AB-890F-CCBD0FCD0B2EQ38127721-66198CFB-D965-4951-9364-2B168E5EB221Q38138557-3A976A0D-AB5B-480F-9E4C-3EE0CED2C963Q38294597-88881FEC-46B6-4253-85A2-5E9E3815757AQ38364169-E91C9322-E15A-4C2C-B3E7-B6E205312091Q38406129-007CACC0-8CBF-4D70-8760-972BC6B1A9E9Q38741339-A2E2EAE8-B7E3-4626-8B6D-82BDC35F4C56Q38853625-DCE891E1-CC60-436D-85FE-5EBC4A137680Q39027016-62C8FCB9-F90D-46EE-805D-9D052BC1FECCQ39276818-B7490916-E3D1-455F-ADB0-485F9AFBBCB8Q39393965-3D422121-2172-417B-A6DF-9647FA89AAAEQ41984684-B8E7664E-E352-4907-B756-B78FD5E65ABB
P2860
Targeting inflammatory pathways for tumor radiosensitization.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting inflammatory pathways for tumor radiosensitization.
@en
Targeting inflammatory pathways for tumor radiosensitization.
@nl
type
label
Targeting inflammatory pathways for tumor radiosensitization.
@en
Targeting inflammatory pathways for tumor radiosensitization.
@nl
prefLabel
Targeting inflammatory pathways for tumor radiosensitization.
@en
Targeting inflammatory pathways for tumor radiosensitization.
@nl
P2860
P1476
Targeting inflammatory pathways for tumor radiosensitization
@en
P2093
Sunil Krishnan
P2860
P304
P356
10.1016/J.BCP.2010.06.039
P407
P577
2010-06-30T00:00:00Z